Why Humana Stock Is Falling During Wednesday’s Session

Humana Inc (NYSE: HUM) shares are trading lower by 2.7% to $487.12 Wednesday afternoon after the company announced CEO Bruce Broussard will step down in the

Humana Inc (NYSE:HUM) shares are trading lower by 2.7% to $487.12 Wednesday afternoon after the company announced CEO Bruce Broussard will step down in the second half of 2024.

The company has appointed Jim Rechtin as President and COO, effective January 8, 2024, as part of a CEO transition plan. Rechtin will eventually take over as CEO, with the current CEO, Bruce Broussard, remaining as a strategic advisor until 2025.

Humana says Rechtin, a healthcare industry veteran, brings substantial experience, having served as President and CEO of Envision Healthcare. This move aims to support Humana’s growth and integrated care strategy.

See Also: Stocks In The Red, Bonds On The Rise As Investors Brace for FOMC Minutes

Meanwhile under Broussard’s leadership, Humana says the company has expanded from an insurer to a broader healthcare company, notably growing its Medicare Advantage membership and enhancing healthcare delivery services.

According to data from Benzinga Pro, Humana has a 52-week high of $571.30 and a 52-week low of $423.29.

Total
0
Shares
Related Posts
Read More

T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale In Company History; The Initial Order Includes Seven T2DX Instruments, Valued At More Than $450,000, With The Potential For Nine Additional Instruments To Be Sold And Deployed

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced the second largest sale of sepsis-driven T2Dx® Instruments in

TTOO